Screener
CytomX Therapeutics CTMX EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from CytomX Therapeutics’s reported figures.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
FAQ
- What is CytomX Therapeutics's EBITDA?
- CytomX Therapeutics (CTMX) reported EBITDA of -$23.75M in Q2 2026.
- How has CytomX Therapeutics's EBITDA changed year-over-year?
- CytomX Therapeutics's EBITDA decreased by 1801.1% year-over-year, from -$1.25M to -$23.75M.
- What is the long-term trend for CytomX Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), CytomX Therapeutics's EBITDA has grown at a -33.8% compound annual growth rate (CAGR), from -$115.9M to -$22.22M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about CytomX Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude